Can-Fite BioPharma (NYSE:CANF) Trading Down 0.1% – What’s Next?

Shares of Can-Fite BioPharma Ltd. (NYSE:CANF) traded down 0.1% during mid-day trading on Monday . The company traded as low as $1.03 and last traded at $1.04. 32,608 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 240,107 shares. The stock had previously closed at $1.04.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, April 15th. Wall Street Zen started coverage on shares of Can-Fite BioPharma in a report on Thursday, April 24th. They set a “sell” rating for the company.

Can-Fite BioPharma Price Performance

The company’s 50 day moving average price is $1.25 and its 200 day moving average price is $1.52. The firm has a market capitalization of $3.77 million, a price-to-earnings ratio of -0.59 and a beta of 1.18.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the quarter. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.